IN2012DN03921A - - Google Patents

Download PDF

Info

Publication number: IN2012DN03921A
Authority: IN; India
Prior art keywords: peptide; diabetes; insulin; disorders; glp
Prior art date: 2004-02-11

Application number

Other languages

English (en)

Inventor

Odile Esther Levy

Michael R Hanley

Carolyn M Jodka

Diana Y Lewis

Christopher J Soares

Soumitra S Ghosh

Souza Lawrence J D

David G Parkes

Christine M Mack

Original Assignee

Amylin Pharmaceuticals Inc

Astrazeneca Pharmaceuticals Lp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-11

Filing date

2005-02-11

Publication date

2015-09-04

2005-02-11 Application filed by Amylin Pharmaceuticals Inc, Astrazeneca Pharmaceuticals Lp filed Critical Amylin Pharmaceuticals Inc

2015-09-04 Publication of IN2012DN03921A publication Critical patent/IN2012DN03921A/en

Links

206010012601 diabetes mellitus Diseases 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
102000004379 Adrenomedullin Human genes 0.000 abstract 2
101800004616 Adrenomedullin Proteins 0.000 abstract 2
YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 abstract 2
102000055006 Calcitonin Human genes 0.000 abstract 2
108060001064 Calcitonin Proteins 0.000 abstract 2
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 abstract 2
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 2
102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 2
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
102400000319 Oxyntomodulin Human genes 0.000 abstract 2
101800001388 Oxyntomodulin Proteins 0.000 abstract 2
108010088847 Peptide YY Proteins 0.000 abstract 2
102100029909 Peptide YY Human genes 0.000 abstract 2
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 abstract 2
229960004015 calcitonin Drugs 0.000 abstract 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 2
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
208000030159 metabolic disease Diseases 0.000 abstract 2
PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
101800001982 Cholecystokinin Proteins 0.000 abstract 1
102100025841 Cholecystokinin Human genes 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
208000030814 Eating disease Diseases 0.000 abstract 1
108010011459 Exenatide Proteins 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
108010092277 Leptin Proteins 0.000 abstract 1
102000016267 Leptin Human genes 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229940107137 cholecystokinin Drugs 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
235000014632 disordered eating Nutrition 0.000 abstract 1
229960001519 exenatide Drugs 0.000 abstract 1
208000004104 gestational diabetes Diseases 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000003054 hormonal effect Effects 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
SFVVQRJOGUKCEG-UHFFFAOYSA-N isoechinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-UHFFFAOYSA-N 0.000 abstract 1
229940039781 leptin Drugs 0.000 abstract 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 abstract 1
SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

IN3921DEN2012 2004-02-11 2005-02-11 IN2012DN03921A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US54340704P	2004-02-11	2004-02-11
PCT/US2005/004178 WO2005077072A2 (en)	2004-02-11	2005-02-11	Hybrid polypeptides with selectable properties

Publications (1)

Publication Number	Publication Date
IN2012DN03921A true IN2012DN03921A (es)	2015-09-04

Family

ID=34860419

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3921DEN2012 IN2012DN03921A (es)	2004-02-11	2005-02-11

Country Status (14)

Country	Link
US (1)	US20060094652A1 (es)
EP (4)	EP2422807A3 (es)
JP (2)	JP2007525495A (es)
KR (3)	KR101427024B1 (es)
CN (3)	CN1961000B (es)
AU (1)	AU2005211755B2 (es)
BR (1)	BRPI0507594A (es)
CA (2)	CA2555877C (es)
IL (1)	IL177229A0 (es)
IN (1)	IN2012DN03921A (es)
NZ (2)	NZ579621A (es)
RU (1)	RU2378285C2 (es)
WO (1)	WO2005077072A2 (es)
ZA (1)	ZA200607190B (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20090281032A1 (en) *	2001-03-01	2009-11-12	Peter Raymond Flatt	Modified CCK peptides
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2556226A1 (en) *	2004-02-11	2006-08-10	Amylin Pharmaceuticals, Inc.	Amylin family peptides and methods for making and using them
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
US7399744B2 (en) *	2004-03-04	2008-07-15	Amylin Pharmaceuticals, Inc.	Methods for affecting body composition
WO2006049681A2 (en) *	2004-08-30	2006-05-11	Bayer Pharmaceuticals Corporation	Selective neuropeptide y2 receptor agonists
CN101035806A (zh) *	2004-10-08	2007-09-12	安米林药品公司	新的糊精家族多肽－6（afp－6）类似物和制备和使用它们的方法
WO2007055728A1 (en) *	2005-11-01	2007-05-18	Amylin Pharmaceuticals, Inc.	Treatment of obesity and related disorders
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
JP2008530130A (ja)	2005-02-11	2008-08-07	アミリン・ファーマシューティカルズ，インコーポレイテッド	Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
EP1891106A2 (en) *	2005-05-05	2008-02-27	Cadila Healthcare Ltd.	Novel compounds as glp-i agonists
WO2007014051A2 (en) *	2005-07-22	2007-02-01	Amylin Pharmaceuticals, Inc.	Use of amylin and amylin agonists as cardioprotective or myoprotective agents
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
EP2330124B1 (en)	2005-08-11	2015-02-25	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
EA014647B1 (ru) *	2005-08-11	2010-12-30	Амилин Фармасьютикалз, Инк.	Гибридные полипептиды с селектируемыми свойствами
DE602005017628D1 (de)	2005-09-22	2009-12-24	Biocompatibles Uk Ltd	Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
WO2007055743A2 (en) *	2005-11-01	2007-05-18	Amylin Pharmaceuticals, Inc.	Treatment of obesity and related disorders
EP2471810A1 (en) *	2006-02-22	2012-07-04	Merck Sharp & Dohme Corporation	Oxyntomodulin derivatives
WO2007104789A2 (en) *	2006-03-15	2007-09-20	Novo Nordisk A/S	Amylin derivatives
CA2646598C (en) *	2006-03-21	2014-08-19	Amylin Pharmaceuticals, Inc.	Peptide-peptidase inhibitor conjugates and methods of using same
ATE444741T1 (de)	2006-05-10	2009-10-15	Biocompatibles Uk Ltd	Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
DK2020990T3 (da)	2006-05-30	2010-12-13	Intarcia Therapeutics Inc	Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
US20100009907A1 (en) *	2006-07-06	2010-01-14	Amylin Pharmaceuticals, Inc.	Glucagon-Like Peptides and Uses Thereof
CN104059071B (zh)	2006-07-10	2016-06-22	Paion英国有限公司	短效苯并二氮杂*盐及其多晶型
KR101200728B1 (ko)	2006-08-09	2012-11-13	인타르시아 세라퓨틱스 인코포레이티드	삼투성 전달 시스템 및 피스톤 조립체
EP2057188B1 (en) *	2006-08-17	2013-07-31	Amylin Pharmaceuticals, LLC	Dpp-iv resistant gip hybrid polypeptides with selectable properties
EP1972349A1 (en) *	2007-03-21	2008-09-24	Biocompatibles UK Limited	GLP-1 fusion peptides conjugated to polymer(s), their production and use
ES2402172T3 (es)	2007-04-23	2013-04-29	Intarcia Therapeutics, Inc	Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
CA2691898A1 (en)	2007-07-06	2009-01-15	Theratechnologies Inc.	Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury
DK2240155T3 (da) *	2008-02-13	2012-09-17	Intarcia Therapeutics Inc	Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
WO2009143285A2 (en)	2008-05-21	2009-11-26	Amylin Pharmaceuticals, Inc.	Exendins to lower cholestrol and triglycerides
JP5703226B2 (ja)	2008-10-21	2015-04-15	ノヴォノルディスクアー／エス	アミリン誘導体
JO3382B1 (ar) *	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2416797A4 (en)	2009-04-10	2013-04-24	Amylin Pharmaceuticals Llc	AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
EP2435061A4 (en)	2009-05-28	2013-03-27	Amylin Pharmaceuticals Inc	DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
RU2753280C2 (ru)	2009-09-28	2021-08-12	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20140066370A1 (en)	2009-11-23	2014-03-06	Amylin Pharmaceuticals, Llc	Polypeptide Conjugate
GB201001333D0 (en)	2010-01-27	2010-03-17	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
CA2797133C (en)	2010-04-27	2019-08-06	Zealand Pharma A/S	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
EP2450039A1 (en)	2010-11-08	2012-05-09	PAION UK Ltd.	Dosing regimen for sedation with CNS 7056 (Remimazolam)
KR101925620B1 (ko)	2010-12-16	2018-12-05	노보 노르디스크 에이/에스	Ｇｌｐ-1 아고니스트 및 ｎ-(8-(2-히드록시벤조일)아미노)카프릴산의 염을 포함하는 고체 조성물
JP2014504588A (ja)	2010-12-22	2014-02-24	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
GB201101459D0 (en)	2011-01-27	2011-03-16	Imp Innovations Ltd	Novel compounds and thier effects on fedding behaviour
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2014521594A (ja)	2011-05-25	2014-08-28	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	長持続期間デュアルホルモンコンジュゲート
JP6359972B2 (ja) *	2011-11-03	2018-07-18	ジーランドファーマアクティーゼルスカブ	Ｇｌｐ−１受容体アゴニストペプチドガストリンコンジュゲート
RU2641198C3 (ru)	2012-03-22	2021-12-10	Ново Нордиск А/С	Композиции glp-1 пептидов и их получение
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211231A1 (en)	2012-12-21	2016-05-20	Sanofi	Exendin-4 derivatives
AR094963A1 (es)	2013-03-04	2015-09-09	Ono Pharmaceutical Co	Reacción de oxidación excelente en el índice de conversión
WO2014158900A1 (en)	2013-03-14	2014-10-02	Indiana University Research And Technology Corporation	Insulin-incretin conjugates
KR20210086717A (ko)	2013-05-02	2021-07-08	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
US10093713B2 (en)	2013-11-06	2018-10-09	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
WO2015067716A1 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Glucagon-glp-1-gip triple agonist compounds
TWI661835B (zh)	2013-11-15	2019-06-11	丹麥商諾佛儂迪克股份有限公司	選擇性ｐｙｙ化合物及其用途
EP3068795B1 (en)	2013-11-15	2019-03-06	Novo Nordisk A/S	Hpyy(1-36) having a beta-homoarginine substitution at position 35
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
CN103665148B (zh) *	2013-12-17	2016-05-11	中国药科大学	一种可口服给药的降糖多肽及其制法和用途
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
JP6956631B2 (ja)	2014-09-15	2021-11-02	アムジェンインコーポレイテッド	二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2015340586B2 (en)	2014-10-29	2020-04-30	Zealand Pharma A/S	GIP agonist compounds and methods
JP6769984B2 (ja)	2015-03-18	2020-10-14	ジーランドファーマアクティーゼルスカブ	アミリン類似体
JOP20200116A1 (ar)	2015-04-24	2017-06-16	Amgen Inc	طرق لعلاج أو الوقاية من الصداع النصفي
KR102650751B1 (ko)	2015-06-03	2024-03-22	인타르시아 세라퓨틱스 인코포레이티드	임플란트 배치 및 제거 시스템들
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
MA43205A (fr)	2015-06-12	2018-09-19	Novo Nordisk As	Composés pyy sélectifs et leurs utilisations
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
SG11201805255TA (en)	2015-12-23	2018-07-30	Amgen Inc	Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
TWI814219B (zh)	2016-05-16	2023-09-01	美商因塔希亞治療公司	升糖素受體選擇性多肽和彼之使用方法
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
IL265099B2 (en) *	2016-09-02	2024-09-01	Christopher J Soares	Pharmaceutical compositions comprising an effective amount of calcitonin gene-related peptide (cgrp) receptor antagonist or pharmaceutically acceptable salt thereof, for treating glaucoma
TWI784968B (zh)	2016-09-09	2022-12-01	丹麥商西蘭製藥公司	澱粉素類似物
WO2018104263A1 (en)	2016-12-06	2018-06-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
AU2017371516C1 (en)	2016-12-09	2021-09-02	Zealand Pharma A/S	Acylated GLP-1/GLP-2 dual agonists
US10835580B2 (en)	2017-01-03	2020-11-17	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
JOP20190177A1 (ar)	2017-01-17	2019-07-16	Amgen Inc	طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
EA201992502A1 (ru)	2017-06-20	2020-04-22	Эмджен Инк.	Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
AR114353A1 (es)	2018-02-02	2020-08-26	Novo Nordisk As	Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
SG11202009629YA (en)	2018-04-02	2020-10-29	Amgen Inc	Erenumab compositions and uses thereof
TWI847981B (zh) *	2018-04-25	2024-07-11	比利時商健生藥品公司	類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
US10875902B2 (en)	2018-04-25	2020-12-29	Janssen Pharmaceutica Nv	Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
US11970523B2 (en) *	2018-07-25	2024-04-30	China Pharmaceutical University	Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof
CN113195524A (zh)	2018-10-11	2021-07-30	因塔西亚治疗公司	人类胰淀素类似物多肽和使用方法
JP7536030B2 (ja)	2019-03-08	2024-08-19	アムジエン・インコーポレーテツド	増殖分化因子１５併用療法
US20220204581A1 (en) *	2019-04-01	2022-06-30	Syracuse University	Monomeric peptide multi-agonist targeting the glp1 receptor and npy receptors
KR102288716B1 (ko) *	2019-10-30	2021-08-12	경상남도	항비만 효능을 갖는 펩타이드 및 이의 용도
CA3156452A1 (en)	2019-11-11	2021-05-20	Boehringer Ingelheim International Gmbh	Npy2 receptor agonists
CN116171282A (zh)	2020-08-07	2023-05-26	勃林格殷格翰国际有限公司	可溶npy2受体激动剂
TWI850611B (zh) *	2020-12-18	2024-08-01	丹麥商諾佛儂迪克股份有限公司	Glp-1及澱粉素受體之共促效劑
CN113929737B (zh) *	2021-10-20	2024-07-23	中国科学院香港创新研究院再生医学与健康创新中心	一种多肽及其作为cck受体激动剂/拮抗剂的应用
WO2024123812A1 (en)	2022-12-05	2024-06-13	Shattuck Labs, Inc.	Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3490597A (en)	1966-07-22	1970-01-20	Purolator Products Inc	Cover plate for spin-on-filter
EP0024807B1 (en)	1979-07-28	1983-11-02	Beecham Group Plc	Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them
US4401593A (en)	1982-02-12	1983-08-30	Armour Pharmaceutical Company	Glycine - 8 calcitonin
US4397780A (en)	1982-02-12	1983-08-09	Armour Pharmaceutical Company	Leucine22 -calcitonin
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US4414149A (en)	1983-03-04	1983-11-08	Armour Pharmaceutical Company	Glycine8 -D-arginine24 calcitonin
US4495097A (en)	1983-04-04	1985-01-22	Armour Pharmaceutical Company	Des-serine2 -glycine8 calcitonin
US4497731A (en)	1983-04-04	1985-02-05	Armour Pharmaceutical Company	Glycine 8-des-tyrosine 22 calcitonin
US5188666A (en)	1983-06-30	1993-02-23	Boccardo Victor N	Paint removing compositions and methods for the manufacture and use thereof
US4597900A (en)	1983-08-22	1986-07-01	Armour Pharmaceutical Co.	Des2 -glycine8 -des22 -calcitonin
US4537716A (en)	1983-12-05	1985-08-27	Armour Pharmaceutical Co.	Des-serine2 or des-glycine2 -leucine22 calcitonin
US4604238A (en) *	1984-12-10	1986-08-05	Armour Pharmaceutical Company	Analogs of calcitonin
US4606856A (en) *	1985-03-18	1986-08-19	Seyler Jay K	[Des-1-amino, 8-glycine]calcitonin
US4652627A (en)	1985-08-16	1987-03-24	Kempe Tomas G	Calcitonin analogs with C-terminal D-amino acid substituents
US4697002A (en) *	1985-12-23	1987-09-29	Kempe Tomas G	Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
US4687839A (en)	1985-12-23	1987-08-18	Kempe Tomas G	Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
NZ229098A (en)	1988-05-13	1992-10-28	Amgen Inc	(bg-csf) bovine granulocyte colony stimulating factor, recombinant methods and pharmaceuticals
ATE135370T1 (de)	1988-12-22	1996-03-15	Kirin Amgen Inc	Chemisch modifizierte granulocytenkolonie erregender faktor
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
DK0512042T3 (da)	1990-01-24	1998-05-11	Douglas I Buckley	GLP-1-analoger anvendelige ved diabetesbehandling
US5234906A (en)	1991-01-10	1993-08-10	Amylin Pharmaceuticals, Inc.	Hyperglycemic compositions
HU222249B1 (hu) *	1991-03-08	2003-05-28	Amylin Pharmaceuticals Inc.	Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5445781A (en)	1991-08-28	1995-08-29	Centro Sviluppo Settori Impiego S.R.L.	Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow
JPH08510205A (ja) *	1993-03-29	1996-10-29	ユニバーシティオブシンシナティ	Ｙｙペプチドのアナログとその用途
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5814316A (en) *	1994-08-05	1998-09-29	Wisconsin Alumni Research Foundation	Compound to mimick a naturally occurring peptide's effect
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en)	1994-11-14	1996-11-12	The Regents Of The University Of California	Treatment of pancreatic tumors with peptide YY and analogs thereof
US5521283A (en) *	1995-01-31	1996-05-28	Eli Lilly And Company	Anti-obesity proteins
US5532336A (en)	1995-01-31	1996-07-02	Eli Lilly And Company	Anti-obesity proteins
US5739106A (en) *	1995-06-07	1998-04-14	Rink; Timothy J.	Appetite regulating compositions
JPH11508895A (ja)	1995-06-30	1999-08-03	イーライ・リリー・アンド・カンパニー	糖尿病を処置する方法
WO1997015322A1 (en)	1995-10-25	1997-05-01	The Regents Of The University Of California	Methods for restoring or enhancing reproductive function in reproductively impaired hosts
CA2246431A1 (en) *	1996-01-19	1997-07-24	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
DE69735477T2 (de)	1996-01-23	2006-11-30	Indevus Pharmaceuticals, Inc., Lexington	Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen
TR199802534T2 (xx)	1996-06-06	1999-03-22	Smithkline Beecham P.L.C.	Leptin (OB Protein) fragmanlar�
US5686511A (en)	1996-06-28	1997-11-11	The Valspar Corporation	Esterifying epoxy resin with carboxyl polymer and quenching
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
PL332458A1 (en)	1996-09-20	1999-09-13	Hoechst Ag	Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii
AU5083098A (en)	1996-10-25	1998-05-22	Icogen Corporation	Use of leptin to stimulate hematopoiesis
DE69831673C5 (de) *	1997-01-07	2015-01-22	Amylin Pharmaceuticals, Llc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
EP0991419A1 (en)	1997-02-25	2000-04-12	Eli Lilly And Company	Treatment of infertility with leptin receptor ligands
IL120733A0 (en)	1997-04-29	1997-08-14	Yeda Res & Dev	Leptin as an inhibitor of cell proliferation
TR199902980T2 (xx)	1997-06-06	2000-05-22	Smithkline Beecham P.L.C.	Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�.
US7910548B2 (en)	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity
BR9811866A (pt)	1997-08-08	2000-08-15	Amylin Pharmaceuticals Inc	Compostos agonistas de exendina
BR9815670A (pt)	1997-11-14	2000-10-17	Amylin Pharmaceuticals Inc	Compostos agonistas de exendina
ATE383867T1 (de)	1997-11-14	2008-02-15	Amylin Pharmaceuticals Inc	Neuartige exendin agonisten
US7745216B2 (en)	1999-02-10	2010-06-29	Curis, Inc.	Methods and reagents for treating glucose metabolic disorders
US7396809B1 (en) *	1999-02-10	2008-07-08	Curis, Inc.	Methods and reagents for treating glucose metabolic disorders
US6162260A (en)	1999-05-24	2000-12-19	Novo Nordisk Biochem North America, Inc.	Single-bath biopreparation and dyeing of textiles
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6734166B1 (en)	2000-02-08	2004-05-11	North Carolina State University	Method of reducing aluminum levels in the central nervous system
US6602997B2 (en)	2000-04-27	2003-08-05	Shin-Etsu Bio, Inc.	Whole cell and cell-debris polysaccharide
CN1483041A (zh) *	2000-12-07	2004-03-17		Glp-1融合蛋白
BR0116206A (pt) *	2000-12-14	2003-12-23	Amylin Pharmaceuticals Inc	Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
JP2005508324A (ja)	2001-09-24	2005-03-31	インペリアルカレッジイノベーションズリミテッド	摂食行動の修正
EP2329839B1 (en)	2002-01-10	2015-09-16	Imperial Innovations Limited	Modification of feeding behavior by GLP-1 and PYY
DE60335639D1 (de)	2002-06-14	2011-02-17	Amylin Pharmaceuticals Inc	Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü
WO2004039832A2 (en)	2002-10-31	2004-05-13	Albany Medical College	Leptin-related peptides
US20040209803A1 (en) *	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
BRPI0411165A (pt) *	2003-05-14	2006-07-11	Emisphere Tech Inc	composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
JP6226510B2 (ja)	2012-01-27	2017-11-08	キヤノン株式会社	画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it)	2013-03-05	2014-09-06	Telecom Italia Spa	Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
US9602308B2 (en)	2014-06-23	2017-03-21	International Business Machines Corporation	Servicing packets in a virtual network and a software-defined network (SDN)
US9816387B2 (en)	2014-09-09	2017-11-14	United Technologies Corporation	Attachment faces for clamped turbine stator of a gas turbine engine
CA2914090C (en)	2015-03-31	2023-08-01	Allen-Vanguard Corporation	Frequency and time domain streaming receiver
US9601471B2 (en)	2015-04-23	2017-03-21	Apple Inc.	Three layer stack structure
US9714199B2 (en)	2015-09-17	2017-07-25	I P Creations Limited	Concealed amalgamated explosive neutralizer and method of manufacture

2005
- 2005-02-11 CN CN2005800120093A patent/CN1961000B/zh not_active Expired - Fee Related
- 2005-02-11 KR KR1020127032622A patent/KR101427024B1/ko not_active Expired - Fee Related
- 2005-02-11 EP EP20110176632 patent/EP2422807A3/en not_active Withdrawn
- 2005-02-11 RU RU2006132294/04A patent/RU2378285C2/ru not_active IP Right Cessation
- 2005-02-11 CA CA2555877A patent/CA2555877C/en not_active Expired - Fee Related
- 2005-02-11 WO PCT/US2005/004178 patent/WO2005077072A2/en active Application Filing
- 2005-02-11 NZ NZ579621A patent/NZ579621A/en not_active IP Right Cessation
- 2005-02-11 AU AU2005211755A patent/AU2005211755B2/en not_active Ceased
- 2005-02-11 CN CN201410138746.9A patent/CN103897066A/zh active Pending
- 2005-02-11 KR KR1020127004103A patent/KR20120034237A/ko not_active Ceased
- 2005-02-11 BR BRPI0507594-7A patent/BRPI0507594A/pt not_active IP Right Cessation
- 2005-02-11 KR KR1020147001171A patent/KR20140011431A/ko not_active Ceased
- 2005-02-11 CN CN201110061194.2A patent/CN102174115B/zh not_active Expired - Fee Related
- 2005-02-11 IN IN3921DEN2012 patent/IN2012DN03921A/en unknown
- 2005-02-11 EP EP11176630A patent/EP2422806A3/en not_active Withdrawn
- 2005-02-11 EP EP11176627A patent/EP2417980A1/en not_active Withdrawn
- 2005-02-11 EP EP05722892.6A patent/EP1718665B1/en not_active Expired - Lifetime
- 2005-02-11 CA CA2849552A patent/CA2849552A1/en not_active Abandoned
- 2005-02-11 NZ NZ548978A patent/NZ548978A/en not_active IP Right Cessation
- 2005-02-11 JP JP2006553217A patent/JP2007525495A/ja active Pending
- 2005-02-11 US US11/055,093 patent/US20060094652A1/en not_active Abandoned
2006
- 2006-08-02 IL IL177229A patent/IL177229A0/en unknown
- 2006-08-29 ZA ZA200607190A patent/ZA200607190B/en unknown
2011
- 2011-06-21 JP JP2011137394A patent/JP5580784B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1961000B (zh)	2011-05-04
RU2006132294A (ru)	2008-03-20
EP2422807A3 (en)	2012-05-30
IL177229A0 (en)	2006-12-10
RU2378285C2 (ru)	2010-01-10
AU2005211755A1 (en)	2005-08-25
WO2005077072A3 (en)	2006-03-02
EP2422807A2 (en)	2012-02-29
NZ548978A (en)	2009-10-30
EP1718665A4 (en)	2008-05-14
EP2422806A2 (en)	2012-02-29
KR20120034237A (ko)	2012-04-10
AU2005211755B2 (en)	2012-03-15
CN102174115B (zh)	2014-05-14
WO2005077072A2 (en)	2005-08-25
KR101427024B1 (ko)	2014-08-05
ZA200607190B (en)	2007-11-28
BRPI0507594A (pt)	2007-07-03
NZ579621A (en)	2011-03-31
EP2417980A1 (en)	2012-02-15
CA2555877C (en)	2015-11-24
KR20140011431A (ko)	2014-01-28
JP2007525495A (ja)	2007-09-06
US20060094652A1 (en)	2006-05-04
CN102174115A (zh)	2011-09-07
CN1961000A (zh)	2007-05-09
JP2011219488A (ja)	2011-11-04
JP5580784B2 (ja)	2014-08-27
KR20130010086A (ko)	2013-01-25
EP1718665B1 (en)	2013-04-10
CN103897066A (zh)	2014-07-02
EP1718665A2 (en)	2006-11-08
CA2555877A1 (en)	2005-08-25
CA2849552A1 (en)	2005-08-25
EP2422806A3 (en)	2012-06-13

Publication	Publication Date	Title
IN2012DN03921A (es)	2015-09-04
Zheng et al.	2024	Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Martin et al.	2011	Incretin‐based therapies–review of the physiology, pharmacology and emerging clinical experience
JP6379300B2 (ja)	2018-08-22	ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途
Lovshin et al.	2009	Incretin-based therapies for type 2 diabetes mellitus
Gupta	2013	Glucagon-like peptide-1 analogues: an overview
Aroda et al.	2011	The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review
Kim et al.	2008	The role of incretins in glucose homeostasis and diabetes treatment
EP4549454A3 (en)	2025-07-09	Gip/glp1 co-agonist compounds
Peters	2010	Incretin-based therapies: review of current clinical trial data
Holst et al.	2017	Semaglutide seems to be more effective the other GLP-1Ras
ZA200606153B (en)	2007-12-27	Intranasal administration of glucose-regulating peptides
Brandt et al.	2018	Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Cho et al.	2013	Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus
CA3107344A1 (en)	2020-01-30	Methods of using a gip/glp1 co-agonist for therapy
SG159551A1 (en)	2010-03-30	Gip analog and hybrid polypeptides with selectable properties
TW201138811A (en)	2011-11-16	Peptide conjugates
MX2022009149A (es)	2022-12-15	Compuestos coagonistas de gip/glp1.
Tanaka et al.	2011	The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors
Aylwin	2005	Gastrointestinal surgery and gut hormones
Will et al.	2017	Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity
Wu et al.	2023	Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes
Grandl et al.	2024	Recent achievements and future directions of anti-obesity medications
Min et al.	2025	A Comprehensive Review on the Pharmacokinetics and Drug− Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist
Apovian	2011	Management of diabetes across the course of disease: minimizing obesity-associated complications